Diagnosis of Fatty Pancreas by FibroScan

NCT ID: NCT07255989

Last Updated: 2025-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-19

Study Completion Date

2024-05-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Example 2: Interventional study The goal of this observational study is to learn know about the use of FibroScan in diagnosis of fatty pancreas in obese and non obese patients which done for the first time at worldwide as well as Egypt .The participtants already came to do liver FibroScan at center of excellence , Benha University , Egypt. Untill now the diagnosis of fatty pancreas by MRI which accurate and specific and diagnose fatty pancreasif it is more than 6.2% . lough the use of abdominal ultrasound also is proved . The use of digital fibroscan which is easy non invasive , unique as well as we can diagnose fibrosis too in the same sitting .So it is highly recommended to be add with examination of liver by fibroscan.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Interventional study done for subjects attend Center of excellence , at Benha University . aged of patients was from 30 years to 70 years old , both male and females , obese or non and DM or non . the patients came to do fibroscan to liver . Lab investigations in the form of CBC ,ESR , liver function tests , kidney function tests. Complete lipid profile , HbA1c .clincal and physical examinations done as regard BMI, past history for metabolic diseases , operations and blood transfusion. FibroScan done first to liver while the patients fastinf at least 3 hours with the know specific position recommendation (banana like ).The position for pancreas examination by fibroScan differe as the patient dorsal position/ recumbancy and his hand behind his head . take deep breah and slighlty keep it . some tilting to the left or right . the probe of fibroscan in the epigastrium under the left rib.which totally differe than liver which in the RT anterior axillary line 8 th intercostal space.picture taken , the unique , novality of this modility is the diagnosis of fibrosis too like liver.Grading of aftty pancreas was done as well as fibrosis of pancreas as follow :S1 =264 dB/m , S2 =276 dB/m and S3 =336 dB/m .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

To Assess Feasibility of the New Application

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Evaluation of uses FibroScan as non invasive method for diagnosis of fatty pancreas
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

As we are care to early diagnosis of fatty pancreas by simple non invasive method

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

the patients evaluated clinically , physically and interview after that examination done by Fibr

Group Type EXPERIMENTAL

meeting about the nutrition

Intervention Type DEVICE

In the meeting time abou the nutrition we talk about our ancient egyptian food which confirmed with Carton already present at center of excellence ,

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

meeting about the nutrition

In the meeting time abou the nutrition we talk about our ancient egyptian food which confirmed with Carton already present at center of excellence ,

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Subjects aged from 30 to 70 years old , both male and females , DM or not obese or non obese

Exclusion Criteria

1. Subjects with significant amount of alcohol consumption or history of alcohol consumption (\>60 g/day).
2. History of steatogenic medications (amiodarone, valproic acid, corticosteroids, tetracyclines).
3. Patients with a previous history of pancreatic disease

\-
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Benha University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof.Reda Mohamed Elbadawy

professor Hepatology , Gastroenterology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Benha University , Egypt

Banhā, Qalyubia Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ministry of Higher education

Identifier Type: OTHER

Identifier Source: secondary_id

CEPHENo5145,2022,BU.

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prevalence of NAFLD in T1DM Patients
NCT06445361 RECRUITING NA
68Ga-FAPI PET/CT in Liver Fibrosis Patients
NCT04533828 UNKNOWN EARLY_PHASE1
Relation Between NAFLD and BM DENSITY
NCT06038253 NOT_YET_RECRUITING
Fatty Liver and Pancreatic Steatosis
NCT06757348 NOT_YET_RECRUITING